Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Indian J Physiol Pharmacol ; 1995 Jul; 39(3): 263-6
Artigo em Inglês | IMSEAR | ID: sea-107956

RESUMO

CMF is a combination of anticancer chemotherapeutic agents Cyclophosphamide, Methotrexate and 5-Fluorouracil. Vitamin E protects the basolateral membrane (BSM) from CMF induced lipid peroxidative damages. Rats were treated intravenously with cyclophosphamide-10 mg, methotrexate-1.0 mg and 5-fluorouracil-10 mg per kg body weight for six cycles. Vitamin E (600 mg/kg body weight) was administered orally, daily. Intestinal basolateral membrane bound ATPases (3.6.1.3), Alkalinephosphatase (3.1.1) and 5'-Nucleotidase (3.1.3.5) were protected by co-administration of vitamin E with CMF. In CMF treated rats the lipid peroxidation levels were found to be elevated with a significant depletion in membrane sulfhydryl groups. In vitamin E co-administered animals, the enzyme activities were found to be restored with concomitant reduction in malondialdehyde levels and an increase in the sulfhydryl groups. The membrane cholesterol and phospholipid levels which were altered in CMF treated rats were bought back to the normal in co-administration of vitamin E.


Assuntos
Animais , Protocolos de Quimioterapia Combinada Antineoplásica/antagonistas & inibidores , Ciclofosfamida/antagonistas & inibidores , Fluoruracila/antagonistas & inibidores , Mucosa Intestinal/efeitos dos fármacos , Metabolismo dos Lipídeos , Peróxidos Lipídicos/metabolismo , Masculino , Membranas/efeitos dos fármacos , Metotrexato/antagonistas & inibidores , Ratos , Ratos Wistar , Tireotropina/metabolismo , Vitamina E/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA